Pyxis Oncology (PYXS) Shares Outstanding (Diluted Average) (2021 - 2025)

Pyxis Oncology (PYXS) has 5 years of Shares Outstanding (Diluted Average) data on file, last reported at $62.1 million in Q4 2025.

• Shares Outstanding (Diluted Average) for Q4 2025 came in at $62.1 million, up 6.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $62.1 million (up 6.33% YoY), and the FY2025 annual result was $62.1 million, up 6.33% from the prior year.
• Shares Outstanding (Diluted Average) retreated to $62.1 million in Q4 2025 per PYXS's latest filing, from $62.6 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $62.6 million in Q3 2025 and troughed at $1.5 million in Q2 2021.
• A 5-year average of $40.7 million and a median of $39.9 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) soared 2100.86% in 2022, then climbed 1.64% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $8.5 million in 2021, then surged by 288.93% to $33.0 million in 2022, then rose by 20.8% to $39.9 million in 2023, then surged by 46.46% to $58.4 million in 2024, then gained by 6.33% to $62.1 million in 2025.
• Business Quant data shows PYXS's Shares Outstanding (Diluted Average) at $62.1 million in Q4 2025, $62.6 million in Q3 2025, and $61.5 million in Q2 2025.